Sintx Technologies, Inc. (NASDAQ: SINT)

SINTX Technologies develops, manufactures, and commercializes silicon nitride biomaterials, composites, and devices for medical and other high-value applications. The company is an advanced ceramics company founded in December 1996 and focuses on medical grade silicon nitride for musculoskeletal and antipathogenic uses. It also supplies silicon nitride parts to customers in the electrical, aerospace, and industrial sectors. SINTX operates its own manufacturing facility in Salt Lake City, Utah, which is FDA registered and holds multiple ISO and AS certifications.

SINTX generates revenue primarily from the sale of silicon nitride-based products, including interbody spinal fusion implants, foot and ankle osteotomy wedges, porous and monolithic silicon nitride components, silicon nitride powder, and coatings. The company also earns revenue from supplying silicon nitride parts to original equipment manufacturers in the aerospace and electrical industries. Additionally, SINTX develops antipathogenic powders and coatings that can be incorporated into products such as face masks, filters, and wound care devices, creating another revenue stream. Revenue is derived from both direct sales to medical institutions and indirect sales through OEM partnerships.

SINTX holds a leading position as the sole provider of FDA cleared silicon nitride medical devices, giving it a unique niche in the advanced ceramics market. Its silicon nitride material combines osteointegration, antibacterial, antifungal, and antiviral properties, distinguishing it from competing biomaterials such as PEEK, traditional oxide ceramics, metal alloys, and allograft bone. The company competes with large orthopedic firms like Medtronic, DePuy Synthes, Stryker, and Zimmer Biomet, which source ceramic components from suppliers such as CeramTec and CoorsTek. In the antipathogenic space, SINTX faces competition from companies like BactiGuard and MicroBan but benefits from proprietary patents covering SARS CoV 2 inactivation and antifungal applications. Its in house manufacturing capabilities and extensive intellectual property portfolio further strengthen its competitive advantage.

SINTX serves hospitals and surgical centers that implant its spinal fusion devices and foot and ankle wedges. The company also sells silicon nitride components to original equipment manufacturers in the aerospace and electrical sectors. A notable customer is CTL Amedica, for which SINTX manufactures interbody spinal fusion devices under an exclusive supply agreement. Additionally, SINTX collaborates with partners developing antipathogenic products for use in face masks, filters, and wound care applications. Its customer base consists primarily of medical device firms, industrial OEMs, and healthcare providers.